[1] Cassidy JW,Caldas C,Bruna A.Maintaining tumor heterogeneity in patient-derived tumor xenografts[J].Cancer Res,2015,75(15):2963-2968.
[2] 陈薛,张贺,师长宏.人源性肿瘤组织原位异种移植模型的特征及研究策略[J].中国比较医学杂志,2018,28(1):118-122.
[3] Izumchenko E,Meir J,Bedi A,et al.Patient-derived xenografts as tools in pharmaceutical development[J].Clin Pharmacol Ther,2016,99(6):612-621.
[4] Monsky WL,Mouta Carreira C,Tsuzuki Y,et al.Role of host microenvironment in angiogenesis and microvascular functions in human breastcancer xenografts:mammary fat pad versus cranial tumors[J].Clin Cancer Res,2002,8(4):1008-1013.
[5] Keysar SB,Astling DP,Anderson RT.A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins[J].Mol Oncol,2013,7(4):776-790.
[6] Choi YY,Lee JE,Kim H,et al.Establishment and characterisa-tion of patient-derived xenografts as paraclinical models for gastric cancer[J].Sci Rep,2016,6:22172.
[7] Ihle NT,Powis G,Kopetz S.PI-3-Kinase inhibitors in colorectal cancer[J].Current Cancer Drug Targets,2011,11(2):190-198.
[8] Krumbach R,Schuler J,Hofmann M,et al.Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models:activation of MET as one mechanism for drug resistance[J].Eur J Cancer,2011,47(8):1231-1243.
[9] 胡斌权,曹博,师长宏.胃癌人源性异种移植模型制备中的问题与策略[J].2017,25(6):643-647.
[10] Visvader JE,Lindeman GJ.Cancer stem cells in solid tumours:accumulating evidence and unresolved questions[J].Nat Rev Cancer,2008,8(10):755-768.
[11] Nguyen LV,Vanner R,Dirks P,et al.Cancer stem cells:an evolving concept[J].Nat Rev Cancer,2012,12(2):133-143.
[12] Valent P,Bonnet D,De Maria R,et al.Cancer stem cell definitions and terminology:the devil is in the details[J].Nat Rev Cancer,2012,12(11):767-775.
[13] Bertolini G,Roz L,Perego P,et al.Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment[J].Proc Natl Acad Sci U S A,2009,106(38):16281-16286.
[14] Jun E,Jung J,Jeong SY,et al.Surgical and oncological factors affecting the successful engraftment of patient-derived xenografts in pancreatic ductal adenocarcinoma[J].Anticancer Res,2016,36(2):517-521.
[15] Gopalakrishnapillai A,Kolb EA,Dhanan P et al.Generation of pediatric leukemia xenograft models in NSG-B2m mice:comparison with NOD/SCID mice[J].Front Oncol,2016,6:162.
[16] 胡斌权,陈城明,张同弟,等.人体肿瘤PDX 移植模型的优与劣[J].实验动物科学,2015,32(5):59-62.
[17] Fujii E,Kato A,Chen YJ,et al.Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse[J].Exp Anim,2014,63(3):289-296.
[18] Hall JC,Marlow LA,Mathias AC,et al.Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin[J].J Transl Med,2016,14(1):129.
[19] Prasad V.Perspective:The precision-oncology illusion[J].Nature,2016,537(7619):S63.
[20] Tannock IF,Hickman JA.Limits to Personalized Cancer Medicine[J].N Engl J Med,2016,375(13):1289-1294. |
